Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oncalis, a biotechnology company, and ChemDiv, a privately-owned, discovery services company, have signed an exclusive agreement for a license to Oncalis a family of PI3K inhibitors.
Subscribe to our email newsletter
Under the terms of the agreement, Oncalis receives a family of compounds targeting different forms of PI3-kinase (PI3-K). PI3-K is an enzyme known to be important in cancer disease progression and potentially in the regulation of certain immune and inflammation-related diseases.
The potential of PI3-K inhibitors has been recently confirmed by advancing development programs from top-tier pharmaceutical companies with this class of compounds. Under the terms of the agreement ChemDiv will perform R&D activities for Oncalis’s lead compounds. Financial terms of the agreement were not disclosed.
ONC-201, the first development candidate from this family, is a potent and selective orally-bioavailable member of a new class of drugs targeting PI3-kinase. ONC-201 has demonstrated highly promising anti-cancer efficacy in pre-clinical cancer models.
Didier Coquoz, CEO of Onacalis, said: “This program expands Oncalis’s internal portfolio and we are extremely excited to successfully move ahead with the development of the PI3-kinase inhibitor ONC-201 in addition to the triple RAF/EGFR/EPHB4 inhibitor ONC-101. We aim to enter clinical trials within the next two years with very promising new anticancer drugs in an extremely promising segment of oncology treatment.”